Mucha Samantha M, deTineo Marcy, Naclerio Robert M, Baroody Fuad M
Section of Otolaryngology-Head and Neck Surgery, The Pritzker School of Medicine, The University of Chicago, Chicago, IL 60637, USA.
Arch Otolaryngol Head Neck Surg. 2006 Feb;132(2):164-72. doi: 10.1001/archotol.132.2.164.
To compare montelukast sodium and pseudoephedrine hydrochloride in the treatment of seasonal allergic rhinitis.
A 2-week, parallel, randomized, double-blind study with rolling enrollment.
Tertiary care medical center.
A total of 58 adult subjects with ragweed allergic rhinitis as documented by positive findings on a skin test to ragweed and history of symptoms during previous seasons.
After recording their own baseline nasal symptoms, nasal peak inspiratory flow (NPIF), and diurnal and nocturnal rhinoconjunctivitis quality of life (QOL) scores, subjects were randomized to receive daily morning oral doses of either pseudoephedrine hydrochloride (240 mg) or montelukast sodium (10 mg) for 2 weeks. They recorded their nasal symptoms and NPIF twice daily during this time, and at the end of the study, they completed another QOL questionnaire and 2 tolerability profiles.
Nasal symptoms, NPIF, QOL scores, and tolerability profiles.
Both active treatments resulted in significant improvements from baseline in all symptoms of allergic rhinitis as well as in all the domains of the QOL questionnaires. When changes from baseline were compared between treatments, there were no significant differences except in the symptom of nasal congestion, for which pseudoephedrine was more effective than montelukast. Both treatments resulted in a significant increase in NPIF over baseline with no significant difference between treatments. Both drugs were well tolerated with no differences in the tolerability profiles between treatments.
Pseudoephedrine and montelukast are equivalent in improving symptoms and QOL and increasing nasal airflow in patients with seasonal allergic rhinitis. The lack of the usual adverse effects in the pseudoephedrine group is ascribed to morning dosing.
比较孟鲁司特钠和盐酸伪麻黄碱治疗季节性变应性鼻炎的效果。
为期2周的平行随机双盲滚动入组研究。
三级医疗中心。
共58例成年患者，经豚草皮肤试验阳性及既往季节症状史证实患有豚草变应性鼻炎。
记录自身基线鼻症状、鼻吸气峰流量（NPIF）以及昼夜变应性鼻结膜炎生活质量（QOL）评分后，患者被随机分为两组，分别每日早晨口服盐酸伪麻黄碱（240 mg）或孟鲁司特钠（10 mg），疗程2周。在此期间，患者每日记录两次鼻症状和NPIF，研究结束时，完成另一项QOL问卷及两份耐受性评估。
鼻症状、NPIF、QOL评分及耐受性评估。
两种有效治疗方法均使变应性鼻炎的所有症状以及QOL问卷的所有领域较基线有显著改善。比较治疗组间的基线变化时，除鼻充血症状外无显著差异，盐酸伪麻黄碱在该症状上比孟鲁司特更有效。两种治疗均使NPIF较基线显著增加，治疗组间无显著差异。两种药物耐受性均良好，治疗组间耐受性评估无差异。
盐酸伪麻黄碱和孟鲁司特在改善季节性变应性鼻炎患者症状、QOL及增加鼻气流方面等效。盐酸伪麻黄碱组缺乏常见不良反应归因于早晨给药。
